Pharmacology · Cholinergic Pharmacology

Muscarinic Antagonists: Pharmacology and Clinical Applications

Belladonna alkaloids, organ-selective agents, anticholinergic toxidrome, and autonomic dysfunction

The critical structural distinction among muscarinic antagonists is quaternary versus tertiary amine: tertiary amines (atropine, scopolamine) are lipid-soluble and cross the blood-brain barrier, producing both peripheral and CNS effects; quaternary amines (ipratropium, glycopyrrolate, trospium) carry a permanent positive charge that blocks BBB penetration, confining effects to the periphery — this property makes trospium the safest overactive bladder agent in cognitively vulnerable patients.
Organ selectivity in muscarinic antagonists is achieved by route (inhaled agents reach the airway without systemic absorption), subtype selectivity (darifenacin has highest M3 selectivity for bladder), and pharmacokinetic design (aclidinium undergoes rapid plasma hydrolysis); tiotropium's slow dissociation from M3 receptors in airways gives it once-daily dosing as first-line COPD maintenance, reducing exacerbations and hospitalizations.
Anticholinergic burden is cumulative and clinically underrecognized — first-generation antihistamines, tricyclic antidepressants, antipsychotics, bladder antimuscarinics, and many other drugs each contribute; in older adults, the cumulative burden causes cognitive impairment, falls, urinary retention, and increased mortality; in Alzheimer disease patients on AChE inhibitors, any anticholinergic drug directly opposes therapy and must be deprescribed.
The anticholinergic toxidrome is remembered as "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter" — the opposite of cholinergic excess in every feature (dry vs. wet, mydriasis vs. miosis, tachycardia vs. bradycardia, secretion absence vs. bronchorrhea); physostigmine reverses the central component, but is absolutely contraindicated in TCA overdose (fatal arrhythmia risk from additive sodium channel blockade — always check QRS before giving).
Autonomic dysfunction management: neurogenic orthostatic hypotension is treated with fludrocortisone (volume expansion), midodrine (alpha-1 agonist prodrug — avoid within 4–6 hours of bedtime), and droxidopa (norepinephrine precursor for sympathetic terminal deficiency); POTS is treated non-pharmacologically first, then with low-dose propranolol or ivabradine; diabetic autonomic neuropathy causes resting tachycardia, orthostatic hypotension, gastroparesis, and neurogenic bladder.

Abbreviations: BBB = blood-brain barrier · CNS = central nervous system · COPD = chronic obstructive pulmonary disease · AChE = acetylcholinesterase · TCA = tricyclic antidepressant · POTS = postural orthostatic tachycardia syndrome · ECG = electrocardiogram

Belladonna Alkaloids — Structural Basis of CNS Penetration

Drug	Structure	CNS Penetration	Key Clinical Uses	Key Adverse Effects
Atropine	Tertiary amine — lipid-soluble, un-ionized at physiological pH	Yes — crosses BBB	Symptomatic bradycardia; organophosphate antidote; cycloplegia; preoperative antisialagogue	Dry mouth, tachycardia, urinary retention, confusion at higher doses
Scopolamine	Tertiary amine — greater central penetration than atropine	Yes — greater than atropine	Motion sickness (transdermal patch); preoperative amnesia	Sedation, confusion, hallucinations; worse in elderly
Ipratropium	Quaternary ammonium — permanent positive charge	No — BBB impermeable; <1% lung absorption	COPD bronchodilation (first-line); adjunct in acute severe asthma	Minimal systemic effects; avoid in narrow-angle glaucoma

Organ-Selective Muscarinic Antagonists

Bladder — Overactive Bladder

Overactive Bladder Antimuscarinics

Oxybutynin — non-selective, mixed mechanism; extended-release and patch reduce AEs
Tolterodine — lower CNS penetration; fewer cognitive AEs
Solifenacin, Darifenacin — M3 preference; once-daily; darifenacin highest M3 selectivity
Trospium — quaternary ammonium; no BBB penetration; safest for cognitively vulnerable patients
Mirabegron — beta-3 agonist (not antimuscarinic); zero anticholinergic burden; first-line alternative

Airway — Bronchodilation

Inhaled Antimuscarinics

Ipratropium — short-acting (4–6 hours); combined with albuterol in acute severe asthma
Tiotropium — once-daily; slow M3 dissociation; first-line COPD maintenance; reduces exacerbations
Aclidinium — twice-daily; rapid plasma hydrolysis limits systemic effects
Umeclidinium — once-daily; often combined with LABA for dual bronchodilator therapy
Long-acting agents not recommended as asthma monotherapy without inhaled corticosteroids

Anticholinergic Burden

Cumulative Muscarinic Burden

Many drug classes carry anticholinergic activity: first-generation antihistamines, TCAs, antipsychotics, disopyramide
Cumulative burden in older adults: cognitive impairment, falls, urinary retention, increased mortality
Alzheimer disease patients on AChE inhibitors: any anticholinergic directly opposes treatment — deprescribe
Prefer trospium or mirabegron in cognitively vulnerable patients

Key rule: assess the total anticholinergic burden, not just the individual drug being prescribed.

The Anticholinergic Toxidrome

Hot as a hare Hyperthermia — sweat glands blocked; heat cannot be dissipated

Dry as a bone All exocrine secretions blocked — dry mouth, dry skin, dry eyes

Red as a beet Cutaneous flushing — vasodilation as the only remaining heat dissipation mechanism

Blind as a bat Mydriasis (dilated fixed pupils) and cycloplegia (loss of accommodation)

Mad as a hatter Agitation, confusion, hallucinations; seizures and coma in severe toxicity

Anticholinergic Toxidrome

Skin: hot, dry, flushed

Pupils: mydriasis (dilated)

Heart rate: tachycardia

Secretions: absent

Bladder: urinary retention

Bowel: ileus, absent sounds

Mental status: agitation, hallucinations

Treatment: physostigmine (after ECG screening)

Cholinergic Toxidrome (Organophosphate)

Skin: wet, diaphoretic, pale

Pupils: miosis (constricted)

Heart rate: bradycardia

Secretions: excessive — bronchorrhea, hypersalivation

Bladder: urinary incontinence

Bowel: diarrhea, cramps

Neuromuscular: fasciculations, weakness

Treatment: atropine + pralidoxime + benzodiazepines

Physostigmine Absolute Contraindication

Physostigmine is the antidote for central anticholinergic toxicity. It is absolutely contraindicated in TCA overdose because it has caused fatal bradyarrhythmias and asystole in that setting. Always check an ECG before administering. QRS complex prolongation = do not give physostigmine.

Autonomic Dysfunction — Drug Summary

Neurogenic Orthostatic Hypotension

Fludrocortisone

Class: Synthetic mineralocorticoid
Mechanism: Renal sodium and water retention → expands plasma volume → raises standing blood pressure
Adverse effects: Supine hypertension, edema, hypokalemia

Neurogenic Orthostatic Hypotension

Midodrine

Class: Alpha-1 agonist prodrug
Mechanism: Converted peripherally → constricts arterioles and veins
Key property: Does not cross BBB — no CNS effects
Caution: No dose within 4–6 hours of bedtime — supine hypertension risk

Neurogenic Orthostatic Hypotension

Droxidopa

Class: Norepinephrine precursor (synthetic amino acid)
Mechanism: Converted to NE in sympathetic terminals by aromatic amino acid decarboxylase
Niche: When terminals are intact but NE synthesis is deficient
Adverse effects: Supine hypertension, headache

Postural Orthostatic Tachycardia Syndrome

POTS Management

Definition: Heart rate rise ≥30 bpm on standing without orthostatic hypotension
Non-pharmacological first: Increased salt and fluid, compression garments, graded exercise
Propranolol (low dose): Reduces exaggerated tachycardia; caution in hyperadrenergic subtype
Ivabradine: Slows SA node without affecting blood pressure; alternative when propranolol not tolerated

Diabetic Autonomic Neuropathy

High-Yield Manifestations

Cardiovascular: Resting tachycardia (loss of vagal tone); orthostatic hypotension; silent myocardial ischemia
GI: Gastroparesis → early satiety, nausea, erratic glycemia
Genitourinary: Neurogenic bladder with large residual urine volumes
Management: Glycemic control to slow progression; symptom-specific pharmacotherapy

Suggested References

Author / Organization	Title	Source
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed. Chapter 8: Cholinoceptor-Blocking Drugs	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed.	McGraw-Hill, 2023
Eglen RM	Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function	Auton Autacoid Pharmacol. 2006;26(3):219–233
Tashkin DP, Celli B, Senn S, et al	A 4-year trial of tiotropium in chronic obstructive pulmonary disease	N Engl J Med. 2008;359(15):1543–1554
Nachum Z, Shahal B, Shupak A, et al	Scopolamine bioavailability in combined oral and transdermal delivery	J Pharmacol Exp Ther. 2001;296(1):121–125
Chapple CR, Cardozo L, Steers W, et al	Solifenacin significantly improves all symptoms of overactive bladder syndrome	Int J Clin Pract. 2006;60(8):959–966
Khullar V, Amarenco G, Angulo JC, et al	Efficacy and tolerability of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder	Eur Urol. 2013;63(2):283–295
Gray SL, Anderson ML, Dublin S, et al	Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study	JAMA Intern Med. 2015;175(3):401–407
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE	The anticholinergic risk scale and anticholinergic adverse effects in older persons	Arch Intern Med. 2008;168(5):508–513
Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME	The use of physostigmine by toxicologists in anticholinergic toxicity	J Med Toxicol. 2015;11(2):179–184
Freeman R, Wieling W, Axelrod FB, et al	Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome	Auton Neurosci. 2011;161(1–2):46–48
Sheldon RS, Grubb BP, Olshansky B, et al	2015 Heart Rhythm Society expert consensus statement on the diagnosis and treatment of POTS, inappropriate sinus tachycardia, and vasovagal syncope	Heart Rhythm. 2015;12(6):e41–e63
Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al	Natural history of pure autonomic failure: a United States prospective cohort	Ann Neurol. 2017;81(2):287–297
Vinik AI, Maser RE, Mitchell BD, Freeman R	Diabetic autonomic neuropathy	Diabetes Care. 2003;26(5):1553–1579
Kerwin EM, D'Urzo AD, Gelb AF, et al	Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients	COPD. 2012;9(2):90–101
Bhidayasiri R, Fahn S, Weiner WJ, et al	Evidence-based guideline: treatment of tardive syndromes	Neurology. 2013;81(5):463–469
Salahudeen MS, Nishtala PS	An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice	Saudi Pharm J. 2017;25(2):165–175
Burns TM, Mauermann ML	The evaluation of polyneuropathies	Neurology. 2011;76(7 Suppl 2):S6–S13
Eddleston M, Buckley NA, Eyer P, Dawson AH	Management of acute organophosphorus pesticide poisoning	Lancet. 2008;371(9612):597–607